Population-Level Data Reveal Widespread HIV Drug Resistance in Sub-Saharan Africa — A Fresh Look at the Numbers
HIV drug resistance is more common across sub-Saharan Africa than previously understood, new population-level data show. In a recent analysis published in BMC Public Health, researchers found that over one-third of people on antiretroviral therapy (ART) carried at least one mutation linked to drug resistance between 2015 and 2019. This underscores how essential sustained viral suppression, consistent ART adherence, and country-specific program factors are in shaping the risk of resistance.
The study authors note that, while ART coverage has expanded dramatically over the last decade, the rise in treatment access has been accompanied by the emergence of HIV drug resistance due to genetic mutations that reduce treatment effectiveness. They highlighted global progress in ART uptake, with an estimated 39.9 million people living with HIV worldwide by the end of 2023 (including about 1.4 million children and 38.6 million adults). Of those living with HIV, 86% knew their status and 77% were receiving ART, yet resistance continues to pose a challenge for long-term treatment success.
To quantify resistance and explore its drivers, the researchers conducted a secondary analysis of data from the Population-based HIV Impact Assessments (PHIA) surveys—the first broadly available surveillance datasets of this kind in sub-Saharan Africa. The analysis spanned nine countries and covered adults with available genotypic resistance testing data collected between 2015 and 2019. Resistance was defined by the presence of at least one mutation associated with reduced efficacy of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), or protease inhibitors (PIs).
In total, 1,008 individuals with resistance data were included. Across the nine countries, the overall HIV drug resistance prevalence stood at 35%. Rwanda showed the highest rate at 72.5%, followed by Namibia at 63.9% and Cameroon at 58.2%. Conversely, Tanzania and Zimbabwe reported lower resistance levels, at 20.7% and 23.1% respectively.
Several factors independently correlated with higher resistance risk. Those who had not achieved viral load suppression faced substantially greater odds of resistance (adjusted odds ratio [aOR] around 0.31 for viral suppression success, though the direction here is reverse; the data indicate unsuppressed viral load is linked to higher resistance risk, with confidence intervals and P-values supporting significance). Previous exposure to ART also doubled the chance of resistance (aOR ≈ 2.60). Age appeared relevant, with individuals 35 years or older showing higher risk, and rural residence coupled with country-specific contexts (notably Rwanda and Zimbabwe) also associated with increased resistance likelihood.
Machine-learning analyses reinforced these insights. They suggested that programmatic and contextual variables—such as prior ART exposure, viral load suppression status, and the national treatment and monitoring environment—were stronger predictors of resistance than basic demographic factors. The model projected that resistance would be most likely among those with prior ART exposure and unsuppressed viral loads, with predicted probabilities reaching up to about 45%.
The researchers emphasize that acquired resistance, rather than resistance present before starting treatment, was the dominant pattern in this population. They connect this to gaps in adherence support, delays in switching regimens when needed, and insufficient treatment monitoring. To curb the rising threat of HIV drug resistance and protect the long-term effectiveness of ART programs in the region, they advocate for continued surveillance and the adoption of context-specific strategies.
In short, the study highlights a clear message: keeping people virally suppressed and consistently adherent to therapy is crucial to limiting drug resistance. But here’s where it gets controversial: even as ART access expands, failures in monitoring, timely regimen adjustments, and adherence support may undermine gains, raising questions about how best to structure treatment programs at the country level. And this is the part most people miss—clear, sustained investment in real-time resistance surveillance and tailored patient support is not optional, but essential for the durability of HIV treatment success. How should health systems balance the push for rapid ART scale-up with the equally urgent need for robust resistance monitoring and adherence infrastructure? Share your thoughts in the comments: should programs prioritize more aggressive monitoring, earlier regimen switches, or broader adherence interventions to curb resistance growth?
